Allosteric Interactions between δ and κ Opioid Receptors in Peripheral Sensory Neurons

Kelly A. Berg, Matthew P. Rowan, Achla Gupta, Teresa A. Sanchez, Michelle Silva, Ivone Gomes, Blaine A. McGuire, Philip S. Portoghese, Kenneth M. Hargreaves, Lakshmi A. Devi, and William P. Clarke

Departments of Pharmacology (K.A.B., M.P.R., T.A.S., M.S., B.A.M., K.M.H., W.P.C.) and Endodontics (K.M.H.), University of Texas Health Science Center, San Antonio, Texas; Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota (P.S.P.); and Departments of Pharmacology and Systems Therapeutics (A.G., I.G., L.A.D.) and Neuroscience, (L.A.D.), Mount Sinai School of Medicine, New York, New York

Received April 4, 2011; accepted November 9, 2011

ABSTRACT

The peripheral δ opioid receptor (DOR) is an attractive target for analgesic drug development. There is evidence that DOR can form heteromers with the κ-opioid receptor (KOR). As drug targets, heteromeric receptors offer an additional level of selectivity and, because of allosteric interactions between protomers, functionality. Here we report that selective KOR antagonists differentially altered the potency and/or efficacy of DOR agonists in primary cultures of adult rat peripheral sensory neurons and in a rat behavioral model of thermal allodynia. In vitro, the KOR antagonist nor-binaltorphimine (nor-BNI) enhanced the potency of [D-Pen²,⁵]-enkephalin (DPDPE), decreased the potency of [D-Ala²,D-Leu⁵]-enkephalin (DADLE), and decreased the potency and efficacy of 4-[(R)-[2S,5R]-4-allyl-2,5-dimethylpiperazin-1-yl][3-methoxyphenoxy]methyl]-N,N-diethylbenzamide (SNC80) to inhibit prostaglandin E₂ (PGE₂)-stimulated adenyl cyclase activity. In vivo, nor-BNI enhanced the effect of DPDPE and decreased the effect of SNC80 to inhibit PGE₂-stimulated thermal allodynia. In contrast to nor-BNI, the KOR antagonist 5'-guanidinonaltrindole (5'-GNTI) reduced the response of DPDPE both in cultured neurons and in vivo. Evidence for DOR-KOR heteromers in peripheral sensory neurons included communoprecipitation of DOR with KOR, a DOR-KOR heteromer selective antibody augmented the antinociceptive effect of DPDPE in vivo, and the DOR-KOR heteromer agonist 6'-GNTI inhibited adenyl cyclase activity in vitro as well as PGE₂-stimulated thermal allodynia in vivo. Taken together, these data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can act as modulators of DOR agonist responses most likely through allosteric interactions between the protomers of the DOR-KOR heteromer.

INTRODUCTION

Management of pain by opioid analgesics is confounded by central adverse effects that limit clinical dosages and treatment paradigms. Consequently, increased attention has been given to analgesia mediated by peripheral opioid receptors. Opioid receptors are expressed in peripheral primary sensory neurons that transduce pain information (nociceptors). It is noteworthy that peripherally restricted opioids generally do not elicit an analgesic response when administered to normal tissue but can produce antinociception when administered to injured or inflamed tissue (Ferreira and Nakamura, 1979; Stein et al., 1989). This finding suggests that some stimulus from the inflamed tissue interacts with opioid receptor systems in nociceptors to make them functionally competent to inhibit nociceptor signaling. We have shown previously that functional competence of rat peripheral opioid receptor systems can be induced by brief pretreatment with inflammatory mediators, such as bradykinin (BK). When applied locally to the rat hind paw (intraplantar), the δ-opioid receptor (DOR) agonist [D-Pen²,⁵]-enkephalin (DPDPE), does not alter PGE₂-induced thermal pain behavior.

ABBREVIATIONS: BK, bradykinin; DPDPE, [D-Pen²,⁵]-enkephalin; PGE₂, prostaglandin E₂; TG, trigeminal ganglion; DADLE, [D-Ala²,D-Leu⁵]-enkephalin; MOR, μ opioid receptor; KOR, κ opioid receptor; DOR, δ opioid receptor; 6'-GNTI, 6'-guanidinonaltrindole; nor-BNI, nor-binaltorphimine; CB, cannabinoid; HEK, human embryonic kidney; PVDF, polyvinyl difluoride; BK, bradykinin; PWL, paw withdrawal latency; NTI, naltrindole; DAMGO, [D-Ala²,N-Me-Phe⁴,Gly⁵-ol]-enkephalin; AT1, angiotensin II type 1.
allodynia. However, when administered 15 min after local injection of BK, DPDPE produces a profound antiallodynic response (Rowan et al., 2009). Likewise, in primary sensory neuronal cultures of adult rat trigeminal ganglion (TG), the DOR agonists DPDPE and [d-Ala²,d-Leu⁵]-enkephalin (DADLE) are ineffective at reducing PGE₂-stimulated cAMP accumulation or BK/PGE₂-stimulated neuropeptide release. However, after brief (15 min) pretreatment with BK (or other activators of Gα₃-mediated signaling), DOR agonists become capable of inhibiting adenyl cyclase activity and neuropeptide release (Patwardhan et al., 2005, 2006). We found similar effects of BK on induction of functional competence to inhibit adenyl cyclase activity and neuropeptide release by activation of the μ-opioid receptor (MOR) system (Berg et al., 2007a,b) as well as for the κ-opioid receptor (KOR) system (Berg et al., 2011). Several studies have demonstrated that DOR and KOR can form heteromers in heterologous expression systems (Jordan and Devi, 1999; Waldhoer et al., 2005; Xie et al., 2005). Heteromers offer intriguing possibilities for drug development in that heteromer-selective ligands would be expected to have greater tissue specificity; such drugs would be effective only in tissues that coexpress the hetero receptor pairs. It is noteworthy that 6'-guanidinonaltrindole (6'-GNTI), originally developed as a KOR agonist (Sharma et al., 2001), seems to have selective DOR/KOR heteromer agonist properties (Waldhoer et al., 2005). 6'-GNTI does not activate DOR and has only weak efficacy at KOR when expressed individually in HEK cells. However, it is a potent and efficacious agonist when both receptors are coexpressed, and its effects can be fully blocked by occupancy of DOR with the antagonist naltirindole or KOR with the antagonist nor-binaltorphimine (nor-BNI). 6'-GNTI has been shown to produce analgesia when administered into the spinal cord, but not the brain, supporting the notion that heteromer-selective ligands will provide greater tissue specificity of action (Waldhoer et al., 2005).

An interesting property of heteromers with respect to drug development is the potential for allosteric interactions between the protomers (Fuxe et al., 2010; Smith and Milligan, 2010; Ková et al., 2011). The interaction between two protomers of a heteromeric pair could influence the affinity, efficacy, or both of a ligand for one of the protomers. For example, the potency of orexin A to promote activation of extracellular signal-regulated kinase in Chinese hamster ovary cells was increased 100-fold by the presence of the CB1 receptor (Hilairet et al., 2003). Ligand binding to the orthosteric site of one protomer of a heteromeric pair can alter the function of a second ligand that binds to the orthosteric site of the second protomer of the pair. With respect to DOR-KOR heteromers expressed in HEK-293 cells, the DOR-selective antagonist, naltirindole, increased the binding of the KOR-selective antagonist, nor-BNI, and vice versa (Xie et al., 2005). Furthermore, Han et al. (2009) recently showed that the conformational state of one protomer of a dopamine D2 receptor heteromer could alter agonist efficacy at the second protomer.

An understanding of the allosteric interactions between protomers of heteromeric pairs of receptors may lead to the development of new drugs with improved efficacy and specificity for treatment of disease. However, although heteromers have been well studied using heterologous expression systems, little is known of the role of heteromers in vivo.

Here we studied the effect of KOR antagonist ligands on the function of DOR agonist ligands in a behavioral model of inflammatory peripheral pain (PGE₂-induced thermal alldynia) and in a primary cell culture model of nociceptor function.

### Materials and Methods

**Materials.** The following compounds were purchased from Sigma-Aldrich (St. Louis, MO): DPDPE, DAMGO, DADLE, SNC80, naltrindole, 5'-guanidinonaltrindole (5'-GNTI), 6'-GNTI, and nor-binaltorphimine (nor-BNI). PGE₂ was purchased from Cayman Chemicals (Ann Arbor, MI). 125I-cAMP was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). Collagenase was from Worthington (Lakewood, NJ). Fetal bovine serum and all other tissue culture reagents were purchased from Invitrogen Corp (Carlsbad, CA). All other drugs and chemicals (reagent grade) were purchased from Sigma-Aldrich.

**Animals.** Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 250 to 300 g were used in this study. The animal study protocol was approved by the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at San Antonio and conformed to International Association for the Study of Pain and federal guidelines. Animals were housed for 1 week with food and water available ad libitum before behavioral testing or harvesting of TG cells.

**Rat Trigeminal Ganglia Culture.** Primary cultures of rat TG cells were prepared as described previously (Patwardhan et al., 2005, 2006; Berg et al., 2007a,b). In brief, fresh TG were washed with Hanks’ balanced salt solution (Ca²⁺/Mg²⁺-free), digested with 3 mg/ml collagenase for 30 min at 37°C, and centrifuged (1000 rpm for 1 min). The pellet was further digested with 0.1% trypsin (15 min) and 167 μg/ml DNase (10 min) at 37°C in the same solution. Cells were pelleted by centrifugation (2 min at 2000 rpm) and resuspended in Dulbecco’s modified Eagle’s medium (high glucose) containing 100 ng/ml nerve growth factor (Harlan, Indianapolis, IN), 10% fetal bovine serum, 50 U/ml penicillin/50 μg/ml streptomycin, 1×1-glutamine, and the mitotic inhibitors 7.5 μg/ml uridine and 17.5 mg/ml 5-fluorodeoxyuridine. After trituration to disrupt tissue, the cell suspension was seeded on polylysine-coated 48-well or 10-cm plates. Cells were pooled from three rats to seed 48-well plates, and cells pooled from six rats were used to seed 10-cm plates. Media was changed 24 and 48 h after plating. On day 5 of culture, cells were refed with serum-free Dulbecco’s modified Eagle’s medium without nerve growth factor. Cells were used on day 6 of culture.

**Coimmunoprecipitation.** The ability of DOR to coimmunoprecipitate with KOR was determined using the Cross-link IP kit according to the manufacturer’s directions (Thermo Fisher Scientific, Waltham, MA) followed by Western blot analysis. In brief, 4 × 10⁵ cells were subjected to cell surface cross-linking with membrane insoluble bis(sulfosuccinimidyl)suberate (1 mM; Pierce) for 30 min at room temperature followed by lysis with 0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% Nonidet P-40, and 5% glycerol, pH 7.4. Lysed material was applied to a spin column (Thermo Fisher Scientific) containing anti-KOR antibody (10 μg; H70; Santa Cruz Biotechnology, Santa Cruz, CA) covalently immobilized to protein A/G agarose beads and incubated overnight at 4°C. After centrifugation, samples (20 μl; 500 μg) were resolved on NuPAGE 4 to 12% SDS-polyacrylamide gradient gels (Invitrogen), transferred to polyvinyl difluoride (PVDF) membrane using the iBlot transfer system (Invitrogen). Western blots were blocked in blocking buffer (1 h, 23°C; Odyssey; LI-COR Biosciences, Lincoln, NE) and incubated overnight with anti-DOR (1:200; Neuromics) or anti-KOR (1:500; Santa Cruz Biotechnology) antibody, followed by the Goat anti-rabbit IR 800 secondary antibody (1:10,000; IRDye 800CW; LI-COR Biosciences). Samples from rat liver (500 μg), which does not contain KOR, and elution buffer only were applied to spin columns (Thermo Fisher Scientific).
Fisher Scientific) containing anti-KOR antibody as control. In addition, samples from TG (500 μg) were applied to spin columns without the anti-KOR antibody. Images were obtained and analyzed with an Odyssey Infrared Western blot imager (LI-COR Biosciences).

**Measurement of Cellular CAMP Levels.** Opioid receptor-mediated inhibition of adenylyl cyclase activity was determined by measuring the amount of cAMP accumulated in the presence of the phosphodiesterase inhibitor, rolipram, and the adenylyl cyclase activator PGE2. Cultures in 48-well plates were washed twice with Hank’s balanced salt solution containing 20 mM HEPES, pH 7.4 (wash buffer). Cells were preincubated in 250 μl of wash buffer per well for 15 min at 37°C (room air) with or without BK (10 μM). To assess opioid agonist-mediated responses, cells were incubated with rolipram (0.1 mM) along with opioid receptor ligands in triplicate for 15 min at 37°C, followed by addition of a maximal concentration of PGE2 (1 μM) and incubation for a further 15 min. Incubations were terminated by aspiration of the buffer and addition of 500 μl of ice-cold absolute ethanol. The ethanol extracts from individual wells were dried under a gentle air stream and reconstituted in 100 μl of 50 mM sodium acetate, pH 6.2. The CAMP content of each well was determined by radioimmunoassay.

**Behavioral Assay.** Opioid agonist-mediated changes in paw withdrawal latency (PWL) to a thermal stimulus were measured with a plantar test apparatus (Hargreaves et al., 1988) as described previously (Rowan et al., 2009). In brief, rats were placed in plastic boxes with a glass floor maintained at 30°C. After a 30-min habituation period, the plantar surface of the hind paw was exposed to a narrow beam of radiant heat through the glass floor. The intensity of the thermal stimulus was adjusted so that baseline PWL values were close to 10 s; cut-off time was 25 s. All drugs were dissolved in phosphate-buffered saline and administered via intraplantar injection (50 μl) into the rat hind paw. To induce functional competence of the opioid receptors (Patwardhan et al., 2005; Berg et al., 2007a, 2007b, 2011), the DOR-KOR ligand 6'-GNTI did not alter PGE2-stimulated cAMP accumulation produced by DPDPE to the left by 10-fold, with no change in the maximal inhibition of 76 ± 8. In the absence of BK, 6'-GNTI, at concentrations up to 1 μM, did not alter PGE2-stimulated cAMP levels. The response to 6'-GNTI in BK-pretreated cells was blocked completely by either the selective KOR antagonist nor-BNI (3 nM, 100 × K) or the selective DOR antagonist naltrindole (NTI; 20 nM, 100 × K) (Fig. 2B).

**Results**

**DOR Coimmunoprecipitates with KOR from Primary Sensory Neurons.** Coimmunoprecipitation experiments were done with primary cultures of rat peripheral sensory neurons. After cell surface cross-linking and immunoprecipitation with anti-KOR antibody, a single, 120-kDa immunoreactive band for DOR was visualized via Western blotting (Fig. 1). Likewise, a 120-kDa immunoreactive band for KOR was also visualized along with a lower molecular mass band at 55 kDa. These data suggest that DOR and KOR form heteromeric complexes in primary sensory neurons in culture.

**Responses to the Putative DOR-KOR Heteromer Agonist 6'-GNTI in Peripheral Sensory Neurons Are Blocked by DOR or KOR Antagonists In Vitro and In Vivo.** In accord with previous observations that opioid receptors expressed in primary sensory neuronal cultures derived from adult rat TG do not inhibit adenylyl cyclase activity unless cells are pretreated with an inflammatory mediator, such as BK (Patwardhan et al., 2005, 2006; Berg et al., 2007a, 2011), the DOR-KOR ligand 6'-GNTI did not alter PGE2-stimulated cAMP levels unless cells were pretreated for 15 min with BK (Fig. 2A). In cells pretreated with BK (10 μM, 15 min), 6'-GNTI inhibited PGE2-stimulated adenylyl cyclase activity with an EC50 of 2 nM (pEC50 8.72 ± 0.14; n = 4) and a maximal inhibition of 76 ± 8. In the absence of BK, 6'-GNTI, at concentrations up to 1 μM, did not alter PGE2-stimulated cAMP levels. The response to 6'-GNTI in BK-pretreated cells was blocked completely by either the selective KOR antagonist nor-BNI (3 nM, 100 × K) or the selective DOR antagonist naltrindole (NTI; 20 nM, 100 × K) (Fig. 2B).

**KOR Antagonists Regulate DOR Agonist Responses in a Ligand-Dependent Manner In Vitro and In Vivo.** In BK-pretreated TG cultures, the DOR agonist DPDPE inhibited PGE2-stimulated cAMP accumulation with a maximal inhibition of 64 ± 6% and an EC50 of 0.5 nM (pEC50 9.31 ± 0.09, n = 6; Fig. 4A). The KOR antagonist nor-BNI (3 nM, 100 × K), shifted the concentration response curve to DPDPE to the left by 10-fold, with no change in the maximal response. In the presence of nor-BNI, the maximal inhibition of PGE2-stimulated cAMP accumulation produced by DPDPE was 63 ± 3% and the EC50 was 0.06 nM (pEC50 10.20 ± 0.06, n = 6; p < 0.05 compared with control, paired t test). Neither basal nor PGE2-stimulated cAMP levels were altered by nor-BNI. Basal levels were 0.75 ± 0.08 pmol/well for vehicle treated cells and 0.82 ± 0.14 pmol/well in the presence of nor-BNI (n = 6, p = 0.67 paired t test). PGE2-stimulated cAMP levels were 166 ± 10% above basal for vehicle and 129 ± 9% above basal with nor-BNI (n = 6; p = 0.357 paired t test).
In contrast to the enhanced sensitivity to DPDPE, nor-BNI decreased the sensitivity to the DOR agonist DAMGO to inhibit PGE$_2$-stimulated cAMP accumulation (Fig. 4B). In the presence of nor-BNI, the concentration-response curve to DAMGO was shifted to the right by 30-fold, without a change in the maximal inhibition. The pEC$_{50}$ values for DAMGO in the absence and presence of nor-BNI were 10.24 ± 0.32 (10 nM) versus 8.74 ± 0.6 (47 nM), respectively (n = 6, p < 0.05 paired t test). The maximal inhibition by DAMGO in the absence and presence of nor-BNI was 62 ± 3.0 versus 61 ± 11%, respectively (n = 6).

Both the potency and the efficacy of the DOR agonist SNC80 were reduced by nor-BNI (Fig. 4C). The pEC$_{50}$ values for SNC80 in the absence and presence of nor-BNI were 10.24 ± 0.32 (1.8 nM), respectively (n = 6, p < 0.05 paired t test). The maximal inhibition by SNC80 in the absence versus the presence of nor-BNI was 62 ± 3.0 versus 61 ± 11%, respectively (n = 6).

nor-BNI did not alter the concentration-response curve to DAMGO, a MOR agonist (Fig. 4D). The maximal inhibition of PGE$_2$-stimulated cAMP accumulation by DAMGO was 72 ± 6.0 versus 66 ± 3.0% in the absence and presence of nor-BNI, respectively (n = 4, p = 0.461 paired t test). The pEC$_{50}$ for DAMGO in the absence and presence of nor-BNI was 7.85 ± 0.14 (10 nM) versus 8.09 ± 0.06 (7 nM), respectively, (n = 4, p = 0.70 paired t test).

Similar results with nor-BNI were seen in the behavioral experiments. Figure 5A shows that DPDPE (0.2 µg) administered by intraplantar injection into the BK-pretreated rat hind paw did not alter PGE$_2$-induced thermal allodynia. This is consistent with our previous study, in which the ED$_{50}$ for DPDPE to inhibit PGE$_2$-induced thermal allodynia was approximately 2.0 µg (Rowan et al., 2009). However, nor-BNI (10 µg) enhanced the effect of this subthreshold dose of DPDPE to completely eliminate the allodynia produced by PGE$_2$. In contrast, nor-BNI eliminated the antiallodynic effect of SNC80 (5 µg, intraplantar; Fig. 5B).

The experiments above demonstrate that the nature of effect of nor-BNI was dependent upon the DOR agonist both in primary culture of sensory neurons and in vivo. Figure 6 shows that the effect on DOR agonist-mediated responses also depends upon the KOR ligand used. In contrast to the enhanced sensitivity of DPDPE produced by nor-BNI (Figs. 4A and 5A), the KOR antagonist 5'-GNTI reduced responsiveness to DPDPE in vitro and in vivo. 5'-GNTI did not alter PGE$_2$-stimulated cAMP accumulation (p = 0.91 paired t test) but dramatically reduced the maximal inhibition of PGE$_2$-stimulated cAMP accumulation produced by DPDPE from 53 ± 3 to 5 ± 4% in the absence and presence of 5'-GNTI, respectively (Fig. 6A; n = 6, p < 0.01 paired t test). Likewise, the antiallodynic effect of an ED$_{50}$ dose of DPDPE (2.0 µg, intraplantar) in BK-pretreated hind paws was completely reduced by 5'-GNTI (Fig. 6B; 2.0 µg, intraplantar).

Effects of a DOR-KOR Heteromer-Selective Monoclonal Antibody In Vivo. A subtractive immunization strategy
Dunnett’s post hoc.

the percentage of PGE2-stimulated cAMP levels and are the mean
Cellular levels of cAMP were determined by RIA. Data are expressed as

pretreated sensory neurons was blocked by either the DOR antagonist

adult rats were pretreated with BK (10

primary cultures of adult sensory neurons. A, TG primary cultures from

were 2.76 ± 0.20 pmol/well and PGE2-stimulated cAMP levels were 67%

were 0.86 for basal and PGE2 cAMP levels, respectively, paired

Effect of 6'-GNTI on PGE2-stimulated adenylyl cyclase activity in
primary cultures of adult sensory neurons. A, TG primary cultures in

was used to generate an antibody that selectively recognized
endothelial DOR-KOR heteromers, as we have done before
(see Supplemental Data and Gupta et al., 2010). Hybridoma clones secreting monoclonal antibodies were screened by en-
zyme-linked immunosorbent assay against untransfected
HEK-293 membranes and HEK-293 membranes expressing
similar levels of KOR or DOR or coexpressing DOR and KOR
receptors. A monoclonal antibody was chosen based on its
ability to recognize an epitope in cells coexpressing DOR and
KOR receptors but not in cells expressing either DOR or KOR
alone (Supplemental Fig. 1). The selectivity of the antibody
for DOR-KOR heteromers was tested by screening against
cells expressing DOR, KOR, or CB1 receptors alone or ex-
pressing MOR-DOR, DOR-KOR, CB1-type 1 angiotensin II
(AT1) receptor, CB1 receptor-CB2 receptor, CB1-MOR, CB1-
KOR heteromers. The antibody recognized an epitope in cells
expressing DOR-KOR heteromers but not the other receptor
complexes (Supplemental Fig. 2).

As shown previously (Fig. 5A), intraplantar injection of
nor-BNI, enhanced the antiallodynic effect of a subthreshold
dose (0.2 μg) of DPDPDE (Fig. 7A). Intraplantar injection of
the DOR-KOR antibody (10 μg) also enhanced the antinoci-
ceptive effect of DPDPE but to an extent considerably greater
than that produced by nor-BNI (Fig. 7A). Whereas DPDPE
completely blocked the alldynic effect of PGE2 after nor-BNI
administration, the DOR-KOR antibody promoted a pro-
found analgesic response from a subthreshold dose of DPDPE.
Injection of an antibody selective for CB1-AT1 receptor het-
eromers did not alter the effect of DPDPDE (Fig. 7B). Neither
nor-BNI nor the DOR-KOR or CB1-AT1 antibodies alone
altered the alldynic effect of PGE2.

Discussion

In this study, we provide evidence for the presence of
DOR-KOR heteromers in peripheral sensory neurons and
demonstrate that KOR antagonist ligands regulate DOR ag-
ionist function, probably via allosteric interactions between
the DOR-KOR protomers. Thus, nor-BNI enhanced the
potency with no change in efficacy of DPDPDE, decreased the
potency with no change in efficacy of DADLE, and decreased
both potency and efficacy of SNC80 in primary cultures of
adult rat peripheral sensory neurons. In contrast to nor-BNI,
the KOR antagonist 5'-GNTI decreased the DPDPE response. The differential effect of KOR antagonists on DOR agonist responses observed in cultured neurons was also observed in a behavioral model of thermal allostodynia. nor-BNI enhanced the antiallodynic response produced by DPDPE and decreased the antiallodynic response produced by SNC80. Also consonant with its effect in cultured neurons, 5'-GNTI decreased the antiallodynic response by DPDPE. Collectively, these parallel studies demonstrate profound, ligand-dependent interactions between KOR and DOR in peripheral sensory neurons, which is a hallmark of allosterism.

Heteromerization between DOR and KOR has been shown in a variety of studies. Epitope-tagged DOR and KOR can be coimmunoprecipitated (Jordan and Devi, 1999; Waldhoer et al., 2005) when coexpressed in HEK cells, and DOR-KOR interactions have been observed in bioluminescence resonance energy transfer experiments in live HEK cells (Wang et al., 2005). Although etorphine promotes DOR internalization in HEK cells, it fails to produce substantial internalization in cells that coexpress KOR (Jordan and Devi, 1999). In addition, coexpression of DOR and KOR changes the affinity values for a variety of ligands (Jordan and Devi, 1999; Bhushan et al., 2004; Waldhoer et al., 2005; Xie et al., 2005). Moreover, 6'-GNTI, previously characterized as a KOR agonist (Sharma et al., 2001), has considerably higher efficacy in cells coexpressing DOR and KOR, and its effects can be fully antagonized by either naltrindole (DOR antagonist) or nor-BNI (KOR antagonist) (Waldhoer et al., 2005).

In the present study, the presence of functional DOR-KOR heteromers in peripheral sensory neurons is suggested by several lines of evidence: 1) DOR coimmunoprecipitated with KOR from primary sensory neuronal cultures, and 2) the putative DOR-KOR heteromer-selective agonist 6'-GNTI (Waldhoer et al., 2005) inhibited PGE2-stimulated cAMP accumulation with high potency and efficacy in vitro and elicited a strong antinociceptive response in vivo, both of which were blocked by either a DOR or KOR antagonist. Third, the antinociceptive response to DPDPE was enhanced by injection of a DOR-KOR heteromer-selective monoclonal antibody into the rat hindpaw. Finally, ligand-dependent effects of KOR antagonists on DOR agonist responses in vitro and in vivo were suggestive of allosteric interactions between DOR-KOR protomers.

Although it is possible that the effects of KOR antagonists on DOR agonist responses occurred as a result of cross talk between KOR and DOR signaling systems, this mechanism seems unlikely. First, for a cross-talk mechanism to be responsible for the observed effects, neither nor-BNI nor 5'-GNTI can be true antagonists, but each must regulate some cellular signaling pathway that alters DOR function. This
pathway must be independent of the Gα-adenyl cyclase pathway, because the KOR antagonists alone did not alter adenylyl cyclase activity. Although nor-BNI and 5′-GNTI have weak inverse agonist properties for the adenylyl cyclase pathway (Wang et al., 2007), to our knowledge, there have been no reports of inverse agonist activity for nonadenylyl cyclase signaling. nor-BNI and 5′-GNTI have weak inverse agonist properties for the adenylyl cyclase pathway (Wang et al., 2007), to our knowledge, there have been no reports of inverse agonist activity for nonadenylyl cyclase signaling. nor-BNI and 5′-GNTI both have agonist activity for c-Jun NH2-terminal kinase phosphorylation (Bruchas and Chavkin, 2010); however, nor-BNI-mediated c-Jun NH2-terminal kinase signaling and its action on DOR would have to be qualitatively different from that of 5′-GNTI, because the actions of these KOR ligands on DPDPE signaling were opposite in direction. Furthermore, for the effect of KOR ligands to be DOR agonist-dependent, the target of the KOR signaling component must be at DOR itself. Changes in any other component of the DOR signaling system beyond the receptor (e.g., adenylyl cyclase) would be expected to regulate all DOR agonists similarly. Moreover, effects of nor-BNI-mediated alterations in KOR signaling on DOR itself must allow for different (opposite) effects on DOR agonist responses (increased versus decreased potency of DPDPE and DADLE by nor-BNI).

We suggest the most parsimonious explanation for the mechanism by which KOR antagonists differentially regulate DOR agonist responsiveness is via allosteric interactions between the protomers of DOR-KOR heteromers. One of the hallmarks of allosterism is that effects are dependent upon the nature of both the allosteric modulator and the orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011). The same allosteric modulator can either increase, decrease, or not alter the activity of an orthosteric ligand (Kenakin, 2009; Smith and Milligan, 2010; Keov et al., 2011).
Allosteric Interactions between DOR and KOR 271

Fig. 7. The effect of a DOR-KOR heteromer selective antibody on DPDPE-mediated thermal antinociception. Animals received intraplantar preinjection with BK (25 μg) without or with nor-BNI (10 μg) and/or a monoclonal, DOR-KOR heteromer-selective antibody (DOR-KOR Ab, 10 μg) (A) or a monoclonal, AT1-CB1 heteromer-selective antibody (AT1-CB1 Ab, 10 μg) (B). Fifteen minutes later, animals received intraplantar DPDPE (0.2 μg, subthreshold) or vehicle (Veh) and PGE2 (0.3 μg). PWL was measured in duplicate at 5-min intervals until 20 min after the last injection. Data are expressed as the change (seconds) from individual baseline (A, 10.85 ± 0.21 s; B, 10.53 ± 0.12 s) values and represent mean ± S.E.M. of four animals per group. ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus the vehicle-treated group by two-way ANOVA with Bonferroni’s multiple comparison test post hoc.

The effect of a DOR-KOR heteromer selective antibody on DPDPE-mediated thermal antinociception. Animals received intraplantar preinjection with BK (25 μg) without or with nor-BNI (10 μg) and/or a monoclonal, DOR-KOR heteromer-selective antibody (DOR-KOR Ab, 10 μg) (A) or a monoclonal, AT1-CB1 heteromer-selective antibody (AT1-CB1 Ab, 10 μg) (B). Fifteen minutes later, animals received intraplantar DPDPE (0.2 μg, subthreshold) or vehicle (Veh) and PGE2 (0.3 μg). PWL was measured in duplicate at 5-min intervals until 20 min after the last injection. Data are expressed as the change (seconds) from individual baseline (A, 10.85 ± 0.21 s; B, 10.53 ± 0.12 s) values and represent mean ± S.E.M. of four animals per group. ***, p < 0.001; **, p < 0.01; *, p < 0.05 versus the vehicle-treated group by two-way ANOVA with Bonferroni’s multiple comparison test post hoc.

Affinity and/or efficacy of DOR agonists. Our estimation of allosteric constants α (affinity) and ξ (efficacy) by fitting the concentration-response curve data for DOR agonist inhibition of cAMP accumulation in the absence and presence of nor-BNI or 5′-GNTI to an allosteric model of agonism (Ke-nakin, 2005; Supplemental Data) suggests that the different actions of KOR ligands can be accommodated by models of allosteric mechanisms.

Allosteric interactions between protomers of heteromeric pairs have been previously reported (see Fuxe et al., 2010; Smith and Milligan, 2010; Keov et al., 2011). In heterologous expression systems, the simple presence of one receptor can alter the affinity and/or efficacy of a ligand for a second receptor (Jordan and Devi, 1999; Waldhoer et al., 2005). It is noteworthy that the conformation of one receptor of a heteromeric pair can influence the affinity and/or efficacy of a ligand at the other protomer. Xie et al. (2005) reported that the DOR antagonist naltrindole increased the affinity of nor-BNI and vice versa. Furthermore, the conformational state of one protomer of a dopamine D2 receptor heteromer differentially altered the efficacy of quinpirole at the second protomer (Han et al., 2009). Here we found that nor-BNI differentially altered the potency and/or efficacy of DOR agonism, depending upon the specific DOR agonist used. In addition, the effect on one DOR agonist, DPDPE, was dependent upon the nature of the KOR antagonist used. Consequently, the most likely mechanism for the ligand-dependent effects of KOR antagonists in peripheral sensory neurons is allosteric modulation between the protomers of a DOR-KOR heteromer.

It has been reported that nor-BNI antagonized the analgesic effect of DPDPE in the mouse tail-flick assay when applied intracerebroventricularly or intrathecally (Portoghese and Lunzer, 2003; Lunzer and Portoghese, 2007). Here we found that intraplantar injection of nor-BNI to rats and direct application of nor-BNI to cultures of rat sensory neurons enhanced DPDPE effects. Whether the differences here relate to differences in route of administration (Lunzer and Portoghese, 2007) or differences in phenotype between peripheral sensory neurons versus CNS neurons or species differences remains to be determined.

It is noteworthy that a monoclonal antibody that selectively binds to DOR-KOR heteromers potentiated the antinociceptive effects of DPDPE in the rat hind paw, similar to but greater than the effect of nor-BNI. In the presence of this antibody, a subthreshold, ineffective dose of DPDPE became capable not only of inhibiting the thermal allodynia produced by PGE2 but also producing close to the maximal possible antinociceptive response in this system. Characterization of this antibody as selective for the DOR-KOR heteromer is presented in the Supplemental Data. Injection of this antibody alone did not alter the transient thermal alllodynia produced by BK (not shown) or that produced by PGE2. These data suggest that the binding of the antibody alters the conformation of the DOR-KOR heteromer such that the affinity and/or efficacy of DPDPE is enhanced.

Although there is evidence for MOR-KOR heteromers (Wang et al., 2005; Chakrabarti et al., 2010; Yekkirala et al., 2011), we did not observe an effect of nor-BNI on the potency or efficacy of the MOR agonist DAMGO. It was recently shown that expression of MOR-KOR heteromers in spinal cord was very low in male rats but high in females and regulated by female sex hormones (Chakrabarti et al., 2010). Thus, the lack of interaction between nor-BNI and DAMGO could be due to low prevalence of MOR-KOR heteromers in the male rats in this study. It is also possible that MOR and KOR are expressed in different cells of the trigeminal ganglion and therefore would not interact allosterically. Alternatively, given the ligand-dependent nature of allosterism, it...
is possible that visualization of interactions between MOR- KOR heteromers requires the use of different ligands.

In summary, our data suggest that DOR-KOR heteromers exist in rat primary sensory neurons and that KOR antagonists can modulate DOR agonist responses, most likely through allosteric interactions between the protomers of the DOR-KOR heteromer. Allosteric regulation of opioid agonist responses may provide opportunities for development of analgesic drugs with greater selectivity, because effects will occur only where both protomers are coexpressed in the same cells. Given the ligand dependence of allosteric interactions, it is important to identify optimal pairs of ligands such that low doses of the analgesic agonist can be used, thereby reducing the incidence and severity of dose-related adverse effects.

Acknowledgments

We thank Dr. Jonathan Javitch and Dr. Marta Filizola for helpful discussions.

Authorship Contributions

Participated in research design: Berg, Devi, and Clarke.

Conducted experiments: Berg, Rowan, Gupta, Sanchez, Silva, Gomes, and McGuire.

Performed data analysis: Berg, Rowan, Gupta, Gomes, Devi, and Clarke.

Wrote or contributed to the writing of the manuscript: Berg, Por
goghes, Hargreaves, Devi, and Clarke.

References


